| Desperately searching for some way to prevent additional infections of his lungs, he and his wife, Marilyn L. Vail, invented the No Colds, No Flus (TM) Eucalyptus Inhaler.
In "Our Stories", first-hand anecdotal accounts are given by those individuals who have repetitively inhaled the vapors from the essential oil from Eucalyptus globulus. These accounts speak for themselves.
In the "References", quotes from the literature are presented by various experts which show the many published benefits of inhaling vapors from Eucalyptus Oil.
The No Colds, No Flus Eucalyptus Inhaler was originally invented to solve the problem of just one person. Now, Inhalation, Inc. is making the Eucalyptus Inhalers commercially available for you. However, please check with your physician before using the No Colds, No Flus Eucalyptus Inhaler.
The co-inventors were awarded their first U.S. Patent on this subject entitled "Methods and Apparatus to Prevent Colds, Flus, and Infections of the Human Respiratory System" that issued as U.S. Patent No. 6,447,816 B1 on September 10, 2002. The co-inventors were awarded their second U.S. Patent on this subject entitled "Methods and Apparatus to Prevent, Treat and Cure Infections of the Human Respiratory System by Pathogens Causing Severe Acute Respiratory Syndrome (SARS)" that issued as U.S. Patent No. 7,048,953 B2 on May 23, 2006. In addition, the co-inventors were also awarded their third U.S. Patent on this subject entitled "Methods and Apparatus to Prevent Colds, Influenzas, Tuberculosis and Opportunistic Infections of the Human Respiratory System" that issued as U.S. Patent No. 7,150,888 B1 on December 19, 2006. Other patents are now pending.
In the following, excerpts are provided from the first U.S. Patent. Other anecdotal accounts are provided by the co-inventors about the use of the Eucalyptus Inhalers. These excerpts and anecdotal accounts are not scientific studies, have not been peer reviewed, have not been reviewed by the USFDA, and simply reflect the opinions of the co-inventors.
The following is quoted from that first U.S. Patent where W. Banning Vail, Ph.D. is the "first inventor":
"BACKGROUND OF THE INVENTION
One of the inventors has poor respiratory health, has had repeated bouts with pneumonia, colds, flu, asthma, and has been recently diagnosed with the initial stages of emphysema - despite all that modern medicine has had to offer. This first inventor also comes from a family known for a long history of respiratory problems. Therefore, the inventors decided to look beyond conventional "modern medicine" to help the first inventor, and as a result, have conceived methods to substantially prevent colds, flus, and infections of the human respiratory system. These methods include the inhalation of the vapors from eucalyptus oil and/or tea tree oil that are theorized to form a protective, and infection-preventing, thin layer within the entire respiratory system, including the lungs, bronchial tubes, and the nasal cavities. This thin layer maintains its anti-pathogenic properties for a period of time following the inhalation of the vapors for at least one-half hour, and perhaps longer. This thin anti-pathogenic layer substantially prevents the initial infection of colds, flus, and other pathogens for a period of time following inhalation. The inventors also propose the prophylactic use of inhaled eucalyptus oil and/or tea tree to prevent additional pathogenic infections such as tuberculosis, which is becoming a major health problem in the United States."
The U.S. Patent is further quoted in the following:
"DESCRIPTION OF THE PREFERRED EMBODIMENTS
Following a business trip to Houston..., the first inventor, W. Banning Vail, Ph.D., returned to Seattle and caught a dreadful form of flu. During this severe illness, the first inventor spent several weeks gasping for breath and nearly died. After several trips to a pulmonary specialist, it was found that about 1/3 of the first inventor's lung capacity had been "eaten up" by some sort of infectious agent. Therefore, the first inventor was diagnosed with a form of emphysema.
The physician further informed the first inventor that if one more such infectious episode should occur, and should that episode result in another 1/6 or more of the first inventor's lung capacity being "eaten up" by an infectious agent, then the first inventor would thereafter become a good candidate for use of oxygen tanks. Further, the first inventor was also diagnosed with asthma. The physician provided additional warnings of potential disaster in light of the first inventor's many childhood bouts with pneumonia that left scars on the lungs. Such warnings were also compounded by the first inventor's habit of smoking, which he quit some 20 years ago.
The first inventor's father, William Banning Vail, Jr., had emphysema, and had used oxygen tanks for perhaps five years. Accordingly, the first inventor feared emphysema and the use of oxygen tanks. The terms such as "emphysema", "asthma", and related diseases are defined and described in Weinstein, 1988, an entire copy of which is incorporated herein by reference. The clinical manifestations of emphysema, asthma, and other respiratory infections are defined and described in Luckmann, 1997, an entire copy of which is incorporated herein by reference.
For many years, it seems almost every time that the first inventor had taken an airplane flight, or had otherwise gone into a public place with a large number of people, he had often caught a cold, a flu, or some other "bug". The terms such as "cold", "flu", "infectious disease", "pathogen" "pathogens", "pathogenesis", "pathologic microorganisms", etc., are defined in Anderson, et. al., 1994, an entire copy of which is incorporated herein by reference. Here, colds include diseases caused by any strain of a rhinovirus. Here, flus include diseases caused by any type of influenza, including those of the respiratory system. Therefore, the first inventor came to fear airplane flights, being in places with many people, etc. because of fear of being infected again with pathogens that could possibly result in death by terminal emphysema.
In Anderson, et. al, 1994, on page 808, the term "risk for infection" is defined as "a state in which an individual is at increased risk for being invaded by pathogenic organisms". Anderson, et. al, 1994, page 808, further states: "Risk factors include inadequate primary defenses, such as broken skin, traumatized tissue, decrease in ciliary action, ...., tissue destruction, ...".
Luckmann, 1997, page 868, also states under the topic of "Nonspecific Body Defenses Against Infection", and under "1. Physical barriers" the following:
"a. Physical, or anatomic, barriers are the 1st line of defense against infection." and
"b. Physical barriers include intact skin and mucous membranes lining the respiratory, gastrointestinal and genitourinary tracts."
Therefore, Luckmann, 1997 specifically refers to the mucous membranes lining the respiratory system as being important to prevent infection, and any less than optimum condition of these membranes would provide another "risk factor" favoring infection by some pathogen.
The first inventor has set forth an hypothesis that his respiratory system and lungs are subject to such "risk factors", and that the first inventor had to invent a new method to prevent invasion by such pathogenic organisms. Consequently, the first inventor has concluded that to minimize the possibility of ending up on oxygen tanks, that it is necessary to prevent the infection of his respiratory system by common pathogens such as pathologic bacteria, viruses, and fungi. It is clear that any one of these pathogens may cause disease. However, the first inventor has the additional hypothesis, that in analogy with many biological systems, it is likely that human diseases can also be caused by a combination of such pathogens that form symbiotic relationships, similar to well-documented mycorrhizal relationships or the like, which may also change in time. For a description of such mechanisms in biology, for example see Audesirk and Audesirk, 1996 on these and related subjects. Therefore, from the first inventor's point of view, it is possible that any one disease may involve bacteria, viruses, and fungi all at one time, and the mix of these may change vs. time as the disease progresses through various stages.
From the first inventor's point of view, many of his illnesses had begun with either cold-like symptoms or flu-like symptoms. If he got very sick, this often progressed into symptoms mimicking those of pneumonia. So, an initial predominantly viral-like infection may evolve into a predominantly bacterial-like infection as time progresses. So, the first inventor views the development of some diseases as progression of various stages, where any one stage may have a peculiar mix of pathogens. The progression of colonies of pathogens vs. time may in fact involve viral, bacterial, and fungal elements called for the purposes herein "symbiotic pathogens" that may make "symbiotic pathogenic colonies". Typically, the composition of those "symbiotic pathogentic colonies" vary with time. As has often been the case in the past, when the first inventor had problems with his respiratory system, standard antibiotics rarely helped. In the first inventor's view, this is because the antibiotics only addressed part of the problem in a typically complex case when "symbiotic pathogens" are causing disease that has at least two components among the three that are viral, bacterial, and fungal components. The view that a given disease is often caused by a time varying mix of bacterial, viral, and fungal pathogens provides the precise reason why the first inventor rarely found commercial antibiotics to be of effective help in overcoming his various lung diseases. Accordingly, the first inventor has theorized that to be able to routinely prevent colds, flus, etc., it is necessary to locate substances that have antiviral and antibacterial and antifungal elements that may be applied to the respiratory system simultaneously.
The first inventor further hypothesized that microscopic portions of his respiratory system at any one time are subject to increased risk of invasion by such pathogens. Any such increased risk site for the purposes herein is defined as a "likely pathogenic invasion site". Once a pathogen "invades" such a "likely pathogenic invasion site", for example within tissue within the lungs, then the pathogens may multiply, causing an infection that may "eat away" the lungs of the first inventor. The first inventor has concluded that he needs new methods and apparatus to prevent or block the invasion of pathogens into a likely pathogenic invasion site within his respiratory system. Put another way, the first inventor sought to find a practical method to reduce the risk of infection of the respiratory system by infectious agents.
This is a tall order. The first inventor had theorized about using certain face masks, filtering the air inhaled by the lungs, and passing inhaled air through U.V. light (with the energy of the U.V. below the threshold to produce ozone).
Then, the first inventor decided to investigate inhaled chemicals to prevent the invasion by pathogens of a likely pathogenic invasion site. Such chemicals need to be highly volatile, non-toxic, and capable of killing bacteria, viruses, and fungi. The second inventor, Marilyn L. Vail, suggested using eucalyptus oil and/or tea tree oil as potential candidates because of her prior research on these substances in her attempts to control Candida albicans.
The inventors identified a class of chemical compounds that may be used to prevent the invasion of pathogens into the respiratory system. They include eucalyptus oil and tea tree oil. The first inventor has found that routinely inhaling these substances has prevented him from getting any colds, flus, or pneumonia ....This is truly remarkable, because the first inventor has often been sick every several months or so during the last several years."
The co-inventors have presented the above quotes from the first U.S. Patent and other anecdotal accounts for consideration of others. However, the co-inventors make no claims based on their own experience that any other person will benefit from the use of inhaled vapors from Eucalyptus globulus and other essential oils. For a current update, please see "W. Banning Vail, Ph.D." under "Our Stories".
Consult with your physician before using any of the Inhalation, Inc. products.
Copyright Inhalation. Inc. 2007 |